Tag: Biotech and Pharma

Oct 27 (Reuters) – Sanofi  shares tumbled more than 15% after the French drugmaker abandoned its 2025 profit target under a plan to list its consumer healthcare business, while boosting its development spending plans to shore up its core innovative drugs business.

Merck reported third-quarter revenue and adjusted earnings that topped expectations.

Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction.

TOKYO, Oct 19 (Reuters) – Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese firm depending on the success of the cell-targeting therapies.

Johnson & Johnson topped quarterly earnings and revenue estimates.

COPENHAGEN, Oct 16 (Reuters) – Novo Nordisk (NOVOb.CO) has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday.

Pfizer slashed its full-year earnings and revenue guidance Friday as it sees demand for its Covid treatment and vaccine wane.

Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.

The Swiss drugmaker announced intentions to spin off the Sandoz business in August, offering stakeholders one Sandoz share for every five Novartis shares via a dividend-in-kind distribution.

Oct 3 (Reuters) – Eli Lilly and Co  will buy cancer therapy developer Point Biopharma Global  for $1.4 billion, the companies said on Tuesday.

Novo Nordisk’s shares fell on Monday after financial news agency MarketWire reported that U.S. drug regulators had recently issued a report detailing quality control lapses at the group’s Clayton, North Carolina plant, citing sources.

 Novartis shareholders on Friday voted in favour of spinning off the Swiss company’s generic-drugs business Sandoz, with investors holding 99.7% of the represented capital supporting the complete separation.

Moderna stock was rising Wednesday after the vaccine maker released positive results from a Phase 3 trial of its mRNA flu vaccine and provided insight on its plans for other vaccines targeting cancer and other diseases

 Eli Lilly’s diabetes drug Mounjaro has gained the backing of Britain’s healthcare cost-effectiveness watchdog, which said it would be a good option for patients with poorly controlled type 2 diabetes.

Scientists have begun investigating whether so-called miracle obesity drugs could be used to treat conditions such as dementia and alcohol addiction after recent trials pointed to the drugs’ efficacy in treating serious health issues.

Moderna’s new Covid vaccine generated a strong immune response against BA.2.86, a highly mutated omicron variant that health officials are watching closely, according to clinical trial data the biotech company released Wednesday.

Johnson & Johnson on Wednesday forecast 12.5% growth in its annual adjusted profit after completing the separation of consumer health company Kenvue .

 Drugmakers Dechra and Hikma along with retailer Marks & Spencer  and technical products provider Diploma are set to join the UK’s blue-chip FTSE 100 index in September, indicative changes announced by FTSE Russell show.

Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated an immune response against the “Eris” subvariant in preclinical studies.

Moderna’s new Covid vaccine generated a robust immune response against the now-dominant Eris variant and another rapidly spreading strain of the virus in an early clinical trial, the biotech company said Thursday.